BioAtla (NASDAQ:BCAB) Issues Earnings Results

BioAtla (NASDAQ:BCAB) released its earnings results on Thursday. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($8.50) by $8.77, FiscalAI reports. The business had revenue of $6.50 million for the quarter.

BioAtla Stock Performance

Shares of BioAtla stock traded up $0.07 on Thursday, reaching $3.45. 148,563 shares of the company were exchanged, compared to its average volume of 49,317. The firm has a market cap of $5.73 million, a price-to-earnings ratio of -0.08 and a beta of 0.78. BioAtla has a 1-year low of $3.12 and a 1-year high of $71.50. The company’s 50-day moving average is $3.65 and its two-hundred day moving average is $5.96.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of BioAtla in a research report on Wednesday, June 3rd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $200.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BCAB. Woodline Partners LP acquired a new stake in BioAtla in the first quarter worth $26,000. ADAR1 Capital Management LLC bought a new position in shares of BioAtla during the fourth quarter worth about $104,000. Susquehanna International Group LLP grew its position in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after acquiring an additional 177,760 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of BioAtla by 55.4% in the 4th quarter. Jane Street Group LLC now owns 346,774 shares of the company’s stock worth $197,000 after acquiring an additional 123,597 shares during the period. Finally, Millennium Management LLC acquired a new stake in shares of BioAtla in the 3rd quarter worth about $235,000. 77.23% of the stock is currently owned by institutional investors.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.